FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884865208> ?p ?o ?g. }

• W2884865208 endingPage "2508" @default.
• W2884865208 startingPage "2501" @default.
• W2884865208 abstract "Disease relapse remains an unmet medical need for patients with Hodgkin lymphoma (HL) receiving an allogeneic hematopoietic cell transplantation (HCT). With the aim of identifying patients at high risk for post-transplant relapse, we retrospectively reviewed 41 HL patients who had received haploidentical (haplo) nonmyeloablative (NMA) HCT with high dose post-transplant cyclophosphamide (PT-Cy) for graft-versus-host (GVHD) prophylaxis. Primary refractory disease, relapse within 6 months from autologous stem cell transplantation, age, pretransplant chemotherapy, HCT comorbidity index (HCT-CI), sex mismatch, tumor burden and pretransplant fluorodeoxyglucose positron emission tomography (FDG-PET) status, assessed by Deauville score, were analyzed as variables influencing outcomes. All but 1 patient engrafted: median time to neutrophil and platelet recovery was 15 (interquartile range, 13 to 23) days and 19 (interquartile range, 12 to 28) days, respectively. Cumulative incidence of severe (grade III to IV) acute graft-versus-host disease (GVHD) and 3-year moderate-severe chronic GVHD was 2.4% and 11.8%, respectively. The 3-year overall (OS), progression free (PFS), and graft relapse-free survival (GRFS) were 75.6%, 43.9%, and 39%, respectively. On multivariate analysis, 3-year OS was significantly worse in patients with HCT-CI ≥3 (hazard ratio [HR], 5.0; 95% confidence interval [CI], 1.1 to 21.8; P = .03). Three-year relapse rate, 3-year PFS, and 3-year GRFS were significantly worse in patients with HCT-CI ≥3 (HR, 3.5; 95% CI, 1.3 to 9.3; P = .01; HR, 3.3; 95% CI, 1.2 to 9.0; P = .02; and HR, 4.2; 95% CI, 1.7 to 9.9; P = .001, respectively) and in patients with a Deauville score ≥4 on pretransplant FDG-PET (HR, 4.4; 95% CI, 1.6-12.4; P = .005, HR, 3.8; 95% CI, 1.5 to 9.7; P = .005; and 3.2; 95% CI, 1.3 to 7.9; P = .01, respectively). On univariate analysis, 3-year NRM was significantly worse only in patients with a HCT-CI ≥3 (HR, 17.6; 95% CI, 1.4 to 221.0). Among relapsed or refractory HL patients undergoing haplo NMA HCT with PT-Cy, pretransplant FDG-PET with a Deauville score ≥4 and HCT-CI ≥3 identified patients at high risk of relapse. Moreover, an HCT-CI ≥3 was associated with higher NRM and lower OS." @default.
• W2884865208 created "2018-08-03" @default.
• W2884865208 creator A5009267255 @default.
• W2884865208 creator A5015250537 @default.
• W2884865208 creator A5018395647 @default.
• W2884865208 creator A5022984958 @default.
• W2884865208 creator A5026031351 @default.
• W2884865208 creator A5029072398 @default.
• W2884865208 creator A5033482554 @default.
• W2884865208 creator A5037808203 @default.
• W2884865208 creator A5042348175 @default.
• W2884865208 creator A5047674295 @default.
• W2884865208 creator A5048234971 @default.
• W2884865208 creator A5059269413 @default.
• W2884865208 creator A5069596141 @default.
• W2884865208 creator A5069969800 @default.
• W2884865208 creator A5071438859 @default.
• W2884865208 creator A5073198334 @default.
• W2884865208 creator A5078922292 @default.
• W2884865208 creator A5083379505 @default.
• W2884865208 creator A5090857723 @default.
• W2884865208 date "2018-12-01" @default.
• W2884865208 modified "2023-09-27" @default.
• W2884865208 title "Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography" @default.
• W2884865208 cites W1676794103 @default.
• W2884865208 cites W1971984984 @default.
• W2884865208 cites W1975053754 @default.
• W2884865208 cites W1978377636 @default.
• W2884865208 cites W1978849352 @default.
• W2884865208 cites W1985460461 @default.
• W2884865208 cites W1997194652 @default.
• W2884865208 cites W2000153687 @default.
• W2884865208 cites W2019111335 @default.
• W2884865208 cites W2022136351 @default.
• W2884865208 cites W2036150888 @default.
• W2884865208 cites W2037029339 @default.
• W2884865208 cites W2038981426 @default.
• W2884865208 cites W2041032819 @default.
• W2884865208 cites W2044804132 @default.
• W2884865208 cites W2046843493 @default.
• W2884865208 cites W2057847137 @default.
• W2884865208 cites W2088783247 @default.
• W2884865208 cites W2114043234 @default.
• W2884865208 cites W2119091791 @default.
• W2884865208 cites W2119147717 @default.
• W2884865208 cites W2122540326 @default.
• W2884865208 cites W2128812336 @default.
• W2884865208 cites W2131900456 @default.
• W2884865208 cites W2168872529 @default.
• W2884865208 cites W2169944840 @default.
• W2884865208 cites W2233814136 @default.
• W2884865208 cites W2289250711 @default.
• W2884865208 cites W2346010008 @default.
• W2884865208 cites W2379365975 @default.
• W2884865208 cites W2532403292 @default.
• W2884865208 cites W2576236969 @default.
• W2884865208 cites W2763445588 @default.
• W2884865208 doi "https://doi.org/10.1016/j.bbmt.2018.07.025" @default.
• W2884865208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30041010" @default.
• W2884865208 hasPublicationYear "2018" @default.
• W2884865208 type Work @default.
• W2884865208 sameAs 2884865208 @default.
• W2884865208 citedByCount "16" @default.
• W2884865208 countsByYear W28848652082019 @default.
• W2884865208 countsByYear W28848652082020 @default.
• W2884865208 countsByYear W28848652082021 @default.
• W2884865208 countsByYear W28848652082022 @default.
• W2884865208 crossrefType "journal-article" @default.
• W2884865208 hasAuthorship W2884865208A5009267255 @default.
• W2884865208 hasAuthorship W2884865208A5015250537 @default.
• W2884865208 hasAuthorship W2884865208A5018395647 @default.
• W2884865208 hasAuthorship W2884865208A5022984958 @default.
• W2884865208 hasAuthorship W2884865208A5026031351 @default.
• W2884865208 hasAuthorship W2884865208A5029072398 @default.
• W2884865208 hasAuthorship W2884865208A5033482554 @default.
• W2884865208 hasAuthorship W2884865208A5037808203 @default.
• W2884865208 hasAuthorship W2884865208A5042348175 @default.
• W2884865208 hasAuthorship W2884865208A5047674295 @default.
• W2884865208 hasAuthorship W2884865208A5048234971 @default.
• W2884865208 hasAuthorship W2884865208A5059269413 @default.
• W2884865208 hasAuthorship W2884865208A5069596141 @default.
• W2884865208 hasAuthorship W2884865208A5069969800 @default.
• W2884865208 hasAuthorship W2884865208A5071438859 @default.
• W2884865208 hasAuthorship W2884865208A5073198334 @default.
• W2884865208 hasAuthorship W2884865208A5078922292 @default.
• W2884865208 hasAuthorship W2884865208A5083379505 @default.
• W2884865208 hasAuthorship W2884865208A5090857723 @default.
• W2884865208 hasBestOaLocation W28848652081 @default.
• W2884865208 hasConcept C119060515 @default.
• W2884865208 hasConcept C126322002 @default.
• W2884865208 hasConcept C141071460 @default.
• W2884865208 hasConcept C143998085 @default.
• W2884865208 hasConcept C207103383 @default.
• W2884865208 hasConcept C2776694085 @default.
• W2884865208 hasConcept C2776755627 @default.
• W2884865208 hasConcept C2777408962 @default.
• W2884865208 hasConcept C2779338263 @default.
• W2884865208 hasConcept C2911091166 @default.

• next